All In Biotech

Drug Trial Radar · NCT04914897

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma

Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

106

Actual

Start

Sep 23, 2021

Primary completion

Jul 18, 2023

Study completion Oct 17, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Primary Objective was: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. The Secondary Objectives were: * To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. * To assess other indicators of antitumor activity. * To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab. * To assess the immunogenicity of SAR444245.

Conditions

  • Pleural Mesothelioma
  • Non-small Cell Lung Cancer

Interventions

  • THOR-707Drug

    Intravenous infusion: solution for infusion

  • PembrolizumabDrug

    Intravenous infusion: solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts A1 and A2: Objective Response Rate (ORR)Time frame: From first dose of study treatment administration (Day 1) up to approximately 21 months
  2. Cohorts B1: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to maximum exposure of study treatment; approximately 14 months
  3. Cohorts C1: Objective Response RateTime frame: From first dose of study treatment administration (Day 1) up to approximately 21 months

Locations

35 sites in 11 countries. Site status is shown where the registry gives one.

  • Thomas Jefferson University Hospital Site Number : 8400009

    Philadelphia, Pennsylvania

  • Thomas Jefferson University - North East Site Number : 8401009

    Philadelphia, Pennsylvania

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0360002

    Richmond, Victoria, Australia

  • Investigational Site Number : 1520003

    Temuco, Chile

  • Investigational Site Number : 1520005

    Santaigo, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520004

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520002

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 1520001

    Santiago, Reg Metropolitana de Santiago, Chile

  • Investigational Site Number : 2500006

    Bordeaux, France

  • Investigational Site Number : 2500005

    Paris, France

  • Investigational Site Number : 2500001

    Saint-Herblain, France

  • Investigational Site Number : 2500003

    Toulouse, France

  • Investigational Site Number : 3800006

    Bologna, Italy

  • Investigational Site Number : 3800004

    Milan, Italy

  • Investigational Site Number : 3800008

    Padova, Italy

  • Investigational Site Number : 3800005

    Aviano (PN), Friuli Venezia Giulia, Italy

  • Investigational Site Number : 3800001

    Rozzano, Milano, Italy

  • Investigational Site Number : 3800002

    Orbassano, Torino, Italy

  • Investigational Site Number : 3920001

    Sapporo, Hokkaido, Japan

  • Investigational Site Number : 6160002

    Poznan, Greater Poland Voivodeship, Poland

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, Poland

  • Investigational Site Number : 6160003

    Gdansk, Pomeranian Voivodeship, Poland

  • Investigational Site Number : 6160004

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Investigational Site Number : 4100002

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100003

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 4100001

    Seoul, Seoul-teukbyeolsi, South Korea

  • Investigational Site Number : 7240002

    Madrid, Spain

  • Investigational Site Number : 7240001

    Madrid, Spain

  • Investigational Site Number : 7240006

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240003

    Girona, Girona [Gerona], Spain

  • Investigational Site Number : 7240004

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 1580003

    Taichung, Taiwan

  • Investigational Site Number : 1580002

    Tainan, Taiwan

  • Investigational Site Number : 1580005

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.